N4 Pharma
Trending Articles
Related Content
Drug Delivery
New-generation silica nanoparticles: the next big thing in siRNA delivery systems for cancer treatment?
In this article, N4 Pharma's Nigel Theobold, CEO, and Dr David Templeton, Technical Director, consider how a novel silica nanoparticle could offer an alternative to current drug delivery approaches for small interfering RNA (siRNA) and meet some of the unmet needs for new, more effective therapies in cancer
Drug Delivery
N4 Pharma highlights potential of Nuvec as gene therapy delivery platform
A preclinical in vivo study found that Nuvec – N4 Pharma’s novel silica-based nanoparticle – formulated with TNF-α pDNA oncotherapy, suppressed tumour growth and improved survival of treated mice compared to untreated controls
Pharmaceutical
Could novel silica nanoparticles answer the COVID-19 vaccine delivery dilemma?
With vast parts of the world still battling SARS-CoV-2 and Europe trying to contend with a second wave and a new strain of the virus, many hopes are pinned on the rollout of approved vaccines to facilitate a return to “normal” life
Drug Delivery
A new paradigm in vaccines and cancer treatments
Specialist pharmaceutical company N4 Pharma is developing Nuvec, a unique non-viral adjuvant delivery system for vaccines and cancer treatments. This silica nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines. Dr Kevin Robinson recently caught up with Nigel Theobald, CEO of N4 Pharma, to find out more